N4 Pharma Plc

N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.